{"id":3920,"date":"2020-09-29T15:49:21","date_gmt":"2020-09-29T13:49:21","guid":{"rendered":"https:\/\/www.ab-science.com\/publications\/"},"modified":"2026-09-29T11:06:26","modified_gmt":"2026-09-29T09:06:26","slug":"publications","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

[vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbabp-section abp-section–intro\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

\n

Publications scientifiques<\/p>\n

Retrouvez les travaux consacr\u00e9s aux programmes d\u2019AB Science.<\/span><\/h2>\n

Les publications sont regroup\u00e9es par programme et donnent acc\u00e8s aux articles ou \u00e0 leur r\u00e9f\u00e9rence scientifique en ligne.<\/p>\n

\n

Scl\u00e9rose en plaques \u2014 4 publications disponibles<\/h3>\n
Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosis<\/span>Vermersch P, et al. \u2014 bioRxiv. 2026. doi:10.64898\/2026.07.02.735783<\/span>\u2197<\/span><\/a>Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease<\/span>Hermine O, et al. \u2014 PLoS One. 2025;20(5):e0322199. doi:10.1371\/journal.pone.0322199<\/span>\u2197<\/span><\/a>Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial<\/span>Vermersch P, et al. \u2014 Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1148. doi:10.1212\/NXI.0000000000001148<\/span>\u2197<\/span><\/a>Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study<\/span>Vermersch P, et al. \u2014 BMC Neurol. 2012;12:36. doi:10.1186\/1471-2377-12-36<\/span>\u2197<\/span><\/a><\/div>\n<\/section>\n
\n

Scl\u00e9rose lat\u00e9rale amyotrophique \u2014 13 publications disponibles<\/h3>\n
Evaluation of long-term amyotrophic lateral sclerosis survivors treated with masitinib in study AB10015<\/span>Ludolph AC, et al. \u2014 medRxiv. 2026. doi:10.64898\/2026.04.10.26350104<\/span>\u2197<\/span><\/a>Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: a subgroup analysis optimizing the benefit-risk profile of masitinib<\/span>Ludolph AC, et al. \u2014 medRxiv. 2025. doi:10.64898\/2025.12.08.25341479<\/span>\u2197<\/span><\/a>Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset \u0394FS for study design and medical practice<\/span>Ludolph AC, et al. \u2014 Muscle Nerve. 2024;70(1):36-41. doi:10.1002\/mus.28101<\/span>\u2197<\/span><\/a>Long-term survival analysis of masitinib in amyotrophic lateral sclerosis<\/span>Mora JS, et al. \u2014 Ther Adv Neurol Disord. 2021;14:17562864211030365. doi:10.1177\/17562864211030365<\/span>\u2197<\/span><\/a>The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS<\/span>Kovacs M, et al. \u2014 Acta Neuropathol Commun. 2021;9:136. doi:10.1186\/s40478-021-01241-3<\/span>\u2197<\/span><\/a>Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A<\/sup> mice<\/span>Harrison JM, et al. \u2014 Neurobiol Dis. 2020;145:105052. doi:10.1016\/j.nbd.2020.105052<\/span>\u2197<\/span><\/a>Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis<\/span>Trias E, et al. \u2014 Glia. 2020;68(6):1165-1181. doi:10.1002\/glia.23768<\/span>\u2197<\/span><\/a>Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial<\/span>Mora JS, et al. \u2014 Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1-2):5-14. doi:10.1080\/21678421.2019.1632346<\/span>\u2197<\/span><\/a>Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS<\/span>Trias E, et al. \u2014 JCI Insight. 2018;3(19):e123249. doi:10.1172\/jci.insight.123249<\/span>\u2197<\/span><\/a>Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS<\/span>Trias E, et al. \u2014 JCI Insight. 2017;2(20):e95934. doi:10.1172\/jci.insight.95934<\/span>\u2197<\/span><\/a>ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?<\/span>Petrov D, et al. \u2014 Front Aging Neurosci. 2017;9:68. doi:10.3389\/fnagi.2017.00068<\/span>\u2197<\/span><\/a>Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis<\/span>Trias E, et al. \u2014 J Neuroinflammation. 2016;13:177. doi:10.1186\/s12974-016-0620-9<\/span>\u2197<\/span><\/a>Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient<\/span>Salvado M, et al. \u2014 World J Gastroenterol. 2015;21(36):10475-10479. doi:10.3748\/wjg.v21.i36.10475<\/span>\u2197<\/span><\/a><\/div>\n<\/section>\n
\n

Maladie d\u2019Alzheimer \u2014 7 publications disponibles<\/h3>\n
Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-\u03baB\/NLRP3\/Caspase-1 signaling pathway<\/span>Jia K, et al. \u2014 Neurosci Lett. 2025;862:138300. doi:10.1016\/j.neulet.2025.138300<\/span>\u2197<\/span><\/a>Mast cell deficiency improves cognition and enhances disease-associated microglia in 5XFAD mice<\/span>Lin CJ, et al. \u2014 Cell Rep. 2023;42(9):113141. doi:10.1016\/j.celrep.2023.113141<\/span>\u2197<\/span><\/a>Mast cell and astrocyte hemichannels and their role in Alzheimer’s disease, ALS, and harmful stress conditions<\/span>Harcha PA, et al. \u2014 Int J Mol Sci. 2021;22(4):1924. doi:10.3390\/ijms22041924<\/span>\u2197<\/span><\/a>Masitinib in mild to moderate Alzheimer\u2019s disease: results from study AB09004<\/span>Dubois B, et al. \u2014 Alzheimers Dement. 2021;17(S9):e049866 (abstract AAIC 2021). doi:10.1002\/alz.049866<\/span>\u2197<\/span><\/a>Effects of chronic masitinib treatment in APPswe\/PSEN1dE9 transgenic mice modeling Alzheimer\u2019s disease<\/span>Li T, et al. \u2014 J Alzheimers Dis. 2020;76(4):1339-1345. doi:10.3233\/JAD-200466<\/span>\u2197<\/span><\/a>Masitinib for the treatment of mild to moderate Alzheimer\u2019s disease<\/span>Folch J, et al. \u2014 Expert Rev Neurother. 2015;15(6):587-596. doi:10.1586\/14737175.2015.1045419<\/span>\u2197<\/span><\/a>Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial<\/span>Piette F, et al. \u2014 Alzheimers Res Ther. 2011;3(2):16. doi:10.1186\/alzrt75<\/span>\u2197<\/span><\/a><\/div>\n<\/section>\n
\n

AB8939 \u2014 5 publications disponibles<\/h3>\n
Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia<\/span>Humbert M, et al. \u2014 bioRxiv. 2025. doi:10.64898\/2025.12.10.692519<\/span>\u2197<\/span><\/a>AB8939, a novel microtubule-destabilizing agent for the treatment of acute myeloid leukemia (abstract EP465)<\/span>Hermine O, et al. \u2014 HemaSphere. 2020;4(S1) (abstract EP465). doi:10.1097\/HS9.0000000000000404<\/span>\u2197<\/span><\/a>In vivo assessment of the next generation microtubule-destabilizing agent AB8939 in patient-derived xenograft models of acute myeloid leukemia<\/span>Goubard A, et al. \u2014 Blood. 2019;134(Supplement 1):5142 (abstract ASH 5142). doi:10.1182\/blood-2019-127143<\/span>\u2197<\/span><\/a>Anticancer activity of a highly potent small molecule tubulin polymerization inhibitor, AB8939<\/span>Humbert M, et al. \u2014 Blood. 2019;134(Supplement 1):2075 (abstract ASH 2075). doi:10.1182\/blood-2019-122540<\/span>\u2197<\/span><\/a>AB8939, a microtubule-destabilizing agent with potential to overcome multidrug resistance, is active across the range (M0-M7) of acute myeloid leukemia subtypes<\/span>Goubard A, et al. \u2014 Blood. 2019;134(Supplement 1):5154 (abstract ASH 5154). doi:10.1182\/blood-2019-127021<\/span>\u2197<\/span><\/a><\/div>\n<\/section>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbabp-section abp-section–intro\u00a0\u00bb][vc_column][vc_column_text] Publications scientifiques Retrouvez les travaux consacr\u00e9s aux programmes d\u2019AB Science. Les publications sont regroup\u00e9es par programme et donnent acc\u00e8s aux articles ou \u00e0 leur r\u00e9f\u00e9rence scientifique en ligne. Scl\u00e9rose en plaques \u2014 4 publications disponibles Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential…<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":3970,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3920","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nPublications – AB Science<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbabp-section abp-section–intro\u00a0\u00bb][vc_column][vc_column_text] Publications scientifiques Retrouvez les travaux consacr\u00e9s aux programmes d\u2019AB Science. Les publications sont regroup\u00e9es par programme et donnent acc\u00e8s aux articles ou \u00e0 leur r\u00e9f\u00e9rence scientifique en ligne. Scl\u00e9rose en plaques \u2014 4 publications disponibles Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T09:06:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/publications\\\/\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/publications\\\/\",\"name\":\"Publications – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-09-29T13:49:21+00:00\",\"dateModified\":\"2026-09-29T09:06:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/publications\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/publications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/publications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Publications – AB Science","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Publications","og_description":"[vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb el_class=\u00a0\u00bbabp-section abp-section–intro\u00a0\u00bb][vc_column][vc_column_text] Publications scientifiques Retrouvez les travaux consacr\u00e9s aux programmes d\u2019AB Science. Les publications sont regroup\u00e9es par programme et donnent acc\u00e8s aux articles ou \u00e0 leur r\u00e9f\u00e9rence scientifique en ligne. Scl\u00e9rose en plaques \u2014 4 publications disponibles Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential…","og_url":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/","og_site_name":"AB Science","article_modified_time":"2026-09-29T09:06:26+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/","url":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/","name":"Publications – AB Science","isPartOf":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#website"},"datePublished":"2020-09-29T13:49:21+00:00","dateModified":"2026-09-29T09:06:26+00:00","breadcrumb":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ab-science.excalibra.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/ab-science.excalibra.com\/fr\/science\/"},{"@type":"ListItem","position":3,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/ab-science.excalibra.com\/fr\/#website","url":"https:\/\/ab-science.excalibra.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ab-science.excalibra.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization","name":"AB Science","url":"https:\/\/ab-science.excalibra.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/comments?post=3920"}],"version-history":[{"count":6,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3920\/revisions"}],"predecessor-version":[{"id":11859,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3920\/revisions\/11859"}],"up":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3970"}],"wp:attachment":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/media?parent=3920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}